MedTrace Logo

Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)

NCT05556083 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-09-27

No results posted yet for this study

Summary

Study Design: Single Blind Placebo Controlled Randomized Trial, aiming to assess the efficacy and safety of adding sildinafile 50 mg to dapoxitine 30 mg in dapoxitine non responding premature ejaculation.

Conditions

  • Premature Ejaculation

Interventions

DRUG

Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet

Single blind placebo randomized controlled trial

DRUG

Placebo oral tablet and Dapoxitine 3mg Oral tablet

Single blind placebo randomized controlled trial

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Mohamed I Algammal, MD. · urologist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-09-29
Completion
2023-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556083 on ClinicalTrials.gov